4 Results for "

CDK9-IN-7

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "CDK9-IN-7" in MCE Product Catalog:

Cat. No.: HY-126251
CAS No.: 2369981-71-3
Purity:  98.05%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .
loading...
    loading...
Cat. No.: HY-149964
CAS No.: 2935587-90-7
Purity:  99.62%
Target:  

PROTACs CDK

Research Areas:  

Cancer

PROTAC CDK9 degrader-7 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .
loading...
    loading...
Cat. No.: HY-162619
Target:  

Apoptosis CDK

Research Areas:  

Cancer

CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity .
loading...
    loading...
Cat. No.: HY-187016
CAS No.: 3052935-75-5
Research Areas:  

Cancer

CDK9 ligand-7 is a CDK9 ligand. CDK9 ligand-7 can serve as a target protein ligand for the synthesis of PROTAC CDK9 degraders, such as CP-07 (HY-149495). CDK9 ligand-7 can be used in prostate cancer research .
loading...
    loading...